Beida Pharmaceuticals: Currently no need to make provision for the loss on the issue of Heyuan Biology.

An investor asked Heda Pharmaceutical: The issuance of He Yuan has exceeded the expected time, and it is expected that it will not be issued. Please specify the specific loss costs. In response, Heda Pharmaceutical replied on the interactive platform on August 24 that the China Securities Regulatory Commission has approved the registration application for the initial public offering of shares of Wuhan He Yuan Biotechnology Co., Ltd. The specific issuance situation, please pay attention to the public information disclosure of He Yuan Biology. Currently, the company does not need to make provisions for losses.